$INVZ
Innoviz Technologies Ltd. Stock $invz

$invz Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000117891324000910 Filed on March 12, 2024

Income Statement

Concept	2023 Q4	2023
Revenue	$14.92M	$20.88M
YoY Change	845.91%	246.43%
Cost Of Revenue	$17.20M	$32.49M
YoY Change	318.11%	119.68%
Gross Profit	-$2.280M	-$11.61M
YoY Change	-10.09%	32.52%
Gross Profit Margin	-15.28%	-55.63%
Selling, General & Admin	$7.411M	$28.31M
YoY Change	2.05%	-3.96%
% of Gross Profit
Research & Development	$22.11M	$92.68M
YoY Change	-15.77%	-2.56%
% of Gross Profit
Depreciation & Amortization	$3.947M	$9.192M
YoY Change	155.8%	23.02%
% of Gross Profit
Operating Expenses	$29.52M	$121.0M
YoY Change	-11.9%	-2.89%
Operating Profit	-$31.80M	-$132.6M
YoY Change	-11.78%	-0.56%
Interest Expense	$1.469M	$9.790M
YoY Change	-24.67%	43.93%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$30.33M	-$122.8M
YoY Change	-11.04%	-2.95%
Income Tax	$122.0K	$642.0K
% Of Pretax Income
Net Earnings	-$30.45M	-$123.5M
YoY Change	-11.28%	-2.69%
Net Earnings / Revenue	-204.14%	-591.37%
Basic Earnings Per Share		-$0.84
Diluted Earnings Per Share	-$0.18	-$0.84
COMMON SHARES
Basic Shares Outstanding	165.4M shares	147.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$39.62M	$39.62M
YoY Change	-59.32%	-59.32%
Cash & Equivalents	$26.28M	$26.28M
Short-Term Investments	$13.34M	$13.34M
Other Short-Term Assets	$111.6M	$111.6M
YoY Change	32.58%	32.58%
Inventory	$1.868M	$1.868M
Prepaid Expenses	$1.500M
Receivables	$7.395M	$7.395M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$160.5M	$160.5M
YoY Change	-14.45%	-14.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$51.26M	$51.26M
YoY Change	68.11%	-10.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$4.813M	$4.813M
YoY Change	-38.61%	-38.61%
Other Assets	$2.707M	$2.707M
YoY Change	3241.98%	3.16%
Total Long-Term Assets	$58.78M	$58.78M
YoY Change	-13.41%	-13.41%
TOTAL ASSETS
Total Short-Term Assets	$160.5M	$160.5M
Total Long-Term Assets	$58.78M	$58.78M
Total Assets	$219.2M	$219.2M
YoY Change	-14.17%	-14.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.036M	$8.036M
YoY Change	-3.96%	-3.96%
Accrued Expenses	$22.25M	$22.25M
YoY Change	260.3%	19.68%
Deferred Revenue	$6.949M
YoY Change	70.24%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$37.23M	$37.23M
YoY Change	14.79%	14.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$28.72M	$28.72M
YoY Change		-7.32%
Total Long-Term Liabilities	$28.72M	$28.72M
YoY Change	-7.32%	-7.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.23M	$37.23M
Total Long-Term Liabilities	$28.72M	$28.72M
Total Liabilities	$65.94M	$65.94M
YoY Change	3.99%	3.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$635.3M
YoY Change	24.12%
Common Stock	$788.6M
YoY Change	12.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$153.3M	$153.3M
YoY Change
Total Liabilities & Shareholders Equity	$219.2M	$219.2M
YoY Change	-14.17%	-14.17%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$30.45M	-$123.5M
YoY Change	-11.28%	-2.69%
Depreciation, Depletion And Amortization	$3.947M	$9.192M
YoY Change	155.8%	23.02%
Cash From Operating Activities	-$14.02M	-$93.05M
YoY Change	-49.65%	-0.38%
INVESTING ACTIVITIES
Capital Expenditures	$481.0K	$6.579M
YoY Change	-90.04%	-70.85%
Acquisitions
YoY Change
Other Investing Activities	$10.70M	$7.643M
YoY Change	-80.56%	-94.83%
Cash From Investing Activities	$10.22M	$1.064M
YoY Change	-79.65%	-99.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$484.0K	$61.86M
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	-484.0K	61.86M
YoY Change	-574.51%	10056.98%
NET CHANGE
Cash From Operating Activities	-14.02M	-93.05M
Cash From Investing Activities	10.22M	1.064M
Cash From Financing Activities	-484.0K	61.86M
Net Change In Cash	-4.284M	-30.13M
YoY Change	-119.05%	-195.93%
FREE CASH FLOW
Cash From Operating Activities	-$14.02M	-$93.05M
Capital Expenditures	$481.0K	$6.579M
Free Cash Flow	-$14.50M	-$99.63M
YoY Change	-55.62%	-14.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40310
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Uri Ariav Street, Bldg. C
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Nitzba
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	300
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, no par value per share
CY2023	dei	Trading Symbol TradingSymbol	INVZ
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26283000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55718000	usd
CY2023Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	53000	usd
CY2022Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	236000	usd
CY2023Q4	invz	Short Term Deposits ShortTermDeposits	105750000	usd
CY2022Q4	invz	Short Term Deposits ShortTermDeposits	80684000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	13335000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	330000	usd
CY2022	invz	Restricted Share Units Vested Value RestrictedShareUnitsVestedValue	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7395000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1762000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1868000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4236000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5774000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3236000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	160458000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	187553000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	4813000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	7840000	usd
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	2623000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26927000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	84000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	81000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	58776000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	67880000	usd
CY2023Q4	us-gaap	Assets Assets	219234000	usd
CY2022Q4	us-gaap	Assets Assets	255433000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8036000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8367000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6949000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4082000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9468000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8693000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8743000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7572000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4034000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3720000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37230000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32434000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28475000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30201000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	240000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	720000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	30982000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	136185264	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	136185264	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	788577000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	703851000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-635288000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-511834000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	153289000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	192017000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	219234000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	255433000	usd
CY2023	us-gaap	Revenues Revenues	20876000	usd
CY2022	us-gaap	Revenues Revenues	6026000	usd
CY2021	us-gaap	Revenues Revenues	5466000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	32490000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	14790000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	10488000	usd
CY2023	us-gaap	Gross Profit GrossProfit	-11614000	usd
CY2022	us-gaap	Gross Profit GrossProfit	-8764000	usd
CY2021	us-gaap	Gross Profit GrossProfit	-5022000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92676000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95107000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93336000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8777000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10300000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	23735000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19535000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19178000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35560000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	120988000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	124585000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	152631000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-132602000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-133349000	usd
CY2022	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	6802000	usd
CY2021	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	4378000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-122812000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-126547000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-153275000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	642000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.54
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.54
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147480521	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135224312	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102859891	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	272815000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-223745000	usd
CY2021	invz	Temporary Equity Convertible Preferred Stock Value Issued Upon Conversion TemporaryEquityConvertiblePreferredStockValueIssuedUponConversion	-272815000	usd
CY2021	invz	Convertible Preferred Stock Value Issued Upon Conversion ConvertiblePreferredStockValueIssuedUponConversion	272815000	usd
CY2021	invz	Issuance Of Common Stock In Connection With Pipe Offering Net Of Issuance Costs IssuanceOfCommonStockInConnectionWithPipeOfferingNetOfIssuanceCosts	164571000	usd
CY2021	invz	Stock Issued During Period Value Under Reverse Merger Net Of Issuance Cost StockIssuedDuringPeriodValueUnderReverseMergerNetOfIssuanceCost	168596000	usd
CY2021	invz	Adjustment To Additional Paid In Capital Reclassification Of Warrant Liabilities To Equity AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesToEquity	4436000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	952000	usd
CY2021	invz	Restricted Share Units Vested Value RestrictedShareUnitsVestedValue	0	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	64736000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153559000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298802000	usd
CY2022	invz	Adjustment To Additional Paid In Capital Reclassification Of Warrant Liabilities To Equity AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesToEquity	29000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	608000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-123454000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-126872000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153559000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	19449000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	64736000	usd
CY2023	invz	Realization Of Investment In Non Marketable Equity Securities RealizationOfInvestmentInNonMarketableEquitySecurities	0	usd
CY2022	invz	Realization Of Investment In Non Marketable Equity Securities RealizationOfInvestmentInNonMarketableEquitySecurities	0	usd
CY2021	invz	Realization Of Investment In Non Marketable Equity Securities RealizationOfInvestmentInNonMarketableEquitySecurities	-2012000	usd
CY2023	invz	Capital Gain Net CapitalGainNet	0	usd
CY2022	invz	Capital Gain Net CapitalGainNet	44000	usd
CY2021	invz	Capital Gain Net CapitalGainNet	0	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	470000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1233000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	577000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	782000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	377000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-620000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5633000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1249000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1993000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2368000	usd
CY2021	invz	Cash Received In Connection With Reverse Merger Net Of Issuance Costs CashReceivedInConnectionWithReverseMergerNetOfIssuanceCosts	121357000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	6530000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	424000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1082000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1997000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2578000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	607000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3076000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	333000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-304000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3469000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-93053000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-93411000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6579000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22567000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3784000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	54000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	invz	Payments To Acquire Bank Deposit PaymentsToAcquireBankDeposit	165600000	usd
CY2022	invz	Payments To Acquire Bank Deposit PaymentsToAcquireBankDeposit	79500000	usd
CY2021	invz	Payments To Acquire Bank Deposit PaymentsToAcquireBankDeposit	375047000	usd
CY2023	invz	Proceeds From Investment In Bank Deposits Net ProceedsFromInvestmentInBankDepositsNet	-141500000	usd
CY2022	invz	Proceeds From Investment In Bank Deposits Net ProceedsFromInvestmentInBankDepositsNet	-230000000	usd
CY2021	invz	Proceeds From Investment In Bank Deposits Net ProceedsFromInvestmentInBankDepositsNet	-145000000	usd
CY2023	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	40000	usd
CY2022	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	2633000	usd
CY2021	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	0	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	51678000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	30103000	usd
CY2023	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	usd
CY2021	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	2178000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1064000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	125354000	usd
CY2022	invz	Issuance Of Ordinary Share Net Of Issuance Cost IssuanceOfOrdinaryShareNetOfIssuanceCost	0	usd
CY2021	invz	Issuance Of Ordinary Share Net Of Issuance Cost IssuanceOfOrdinaryShareNetOfIssuanceCost	217507000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	456000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	609000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	952000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26225000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55954000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24541000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50766000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26336000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55954000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24541000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	94000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	703000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	128000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	237000	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	272815000	usd
CY2023	invz	Non Cash Purchase Of Property And Equipment NonCashPurchaseOfPropertyAndEquipment	831000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55718000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23640000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	53000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	236000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	901000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26336000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55954000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24541000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<div> <div> <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)"> <tr> <td style="vertical-align:top;font-weight:bold;width:56pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE 1: -</span></span></span></span></td> <td style="vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">GENERAL</span></span></span></span></span></td> </tr> </table> </div> <div> <div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:56.7pt"> </td> <td style="width:14.2pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Innoviz Technologies Ltd. and its subsidiaries (the “Company” or “Innoviz”) is a Tier-1 direct supplier of high-performance, automotive grade LiDAR sensors and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. </span></span>The Company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles and trucks. The Company operates as a single operating segment.</div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:56.7pt"> </td> <td style="width:14.2pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company was incorporated on January 18, 2016, under the laws of the state of Israel.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:56.7pt"> </td> <td style="width:14.2pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 10, 2020, the Company entered into definitive agreements in connection with a merger (the “Transactions”) with Collective Growth Corporation (“Collective Growth”), a special purpose acquisition company, that resulted in Collective Growth becoming a wholly owned subsidiary of the Company upon the consummation of the Transactions on April 5, 2021 (the “Closing Date”).</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Transactions were accounted for as a recapitalization in accordance with accounting principles generally accepted in the United States (“GAAP”).</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Upon closing of the Transactions, 20,418,209 Series A Convertible Preferred Shares, 15,906,053 Series B Convertible Preferred Shares, 3,032,940 Series B-1 Convertible Preferred Shares, 28,216,005 Series C Convertible Preferred Shares and 3,045,792 Series C-1 Convertible Preferred Shares were automatically converted into 70,618,999 Ordinary Shares of no-par value.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the Transactions (i) 1,875,000 shares of Class B common shares of Collective Growth, after taking into account the forfeiture of shares by the holders of Class B common shares of Collective Growth, were each exchanged for one ordinary share of no-par value of the Company (“Company Ordinary Share”), (ii) each outstanding share of Class A common shares of Collective Growth was exchanged for one Company Ordinary Share, and (iii) each outstanding warrant of Collective Growth was assumed by the Company and became one warrant of the Company (each, a “Company Warrant”) exercisable for Company Ordinary Shares (see Note 2a).</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the Transactions, the Company incurred direct and incremental costs of $102,945 related to the Transactions, consisting primarily of investment banking, legal, accounting and other professional fees, out of which $101,115 were recorded to additional paid-in capital as a reduction of proceeds and $1,830 have been accounted for as General and Administrative expenses as part of the consolidated statement of operations.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, on the Closing Date, in connection with the consummation of the Transactions (i) the Company issued Perception Capital Partners LLC (“Perception”) an aggregate of 3,027,747 Company Warrants, (ii) the Company issued Antara Capital Master Fund LP (“Antara”) an aggregate of 3,002,674 Company Ordinary Shares and 3,784,753 Company Warrants and (iii) the Company issued Company’s Management 2,500,000 Ordinary Shares and 3,500,000 options (see also Note 12).</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, in the event that the earnout Target is reached during the Earnout Period (both “Target” and “Earnout Period” as defined in the Business Combination Agreement), then: (A) Perception shall also be entitled to receive up to 2,089,882 of additional Company Ordinary Shares, (B) Antara shall also be entitled to receive up to 312,296 of additional Company Ordinary Shares and (C) certain members of the Company’s management shall be entitled to receive up to 1,250,000 of additional Company Ordinary Shares. As of December 31, 2023, the Target was not reached and therefore no additional Company Ordinary Shares have been issued (see also Note 12).</span></span></div> <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"> </div> <div></div> <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additionally, on the Closing Date, the Company completed the sale of Ordinary Shares to certain accredited investors (“Investors”), at a price per share of $10, for gross proceeds to the Company of $229,500, pursuant to a series of subscription agreements (“Subscription Agreements” or “PIPE”) entered into by the Company and the Investors concurrently with the execution of the Business Combination Agreement.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Upon closing of the Transactions, the Company has adopted, amended and restated articles of association to align such organizational documents with consistent with those of a publicly held company and has become a publicly traded company.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:1.1pt;margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s ordinary shares and public warrants were listed on the Nasdaq Stock Market LLC under the trading symbols “INVZ” and “INVZW”, respectively, on April 5, 2021.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:56.7pt"> </td> <td style="width:14.2pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the Company’s principal source of liquidity includes its cash and cash equivalents in the amount of $26,283, bank deposits in the amount of $105,750 and marketable securities in the amount of $18,148, which is sufficient to finance its business plan for at least 12 months from the date these financial statements are issued. As the Company achieves further commercial success, it may need to obtain additional funding to support its continuing operations. If the Company is unable to raise capital when and if needed, it may need to reduce or eliminate some of its research and development programs.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:56.7pt"> </td> <td style="width:14.2pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve.<span style="font-weight:bold"> </span>The intensity and duration of the war is difficult to predict, as such are the war’s economic implications on the Company’s operational and financial performance. The Company considered the impact of the war and determined that there were no material adverse impacts on the consolidated financial statements, including related significant estimates made by management, for the period ended December 31, 2023.</span></span></div> </td> </tr> </table> </div> </div> </div>
CY2021Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	101115000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.5
CY2022Q4	invz	Redemption Price Of Outstanding Warrants In Whole And Not In Part RedemptionPriceOfOutstandingWarrantsInWholeAndNotInPart	0.01
CY2023Q4	invz	Number Of Private Warrants Held By Initial Purchasers NumberOfPrivateWarrantsHeldByInitialPurchasers	1465000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	453750	shares
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5774000	usd
CY2023Q4	invz	Revenue Remaining Performance Obligation Recorded As Short Term Deferred Revenues RevenueRemainingPerformanceObligationRecordedAsShortTermDeferredRevenues	6145000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	330000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt" width="100%"> <tr style="page-break-inside:avoid"> <td style="width:56.7pt"> </td> <td style="text-align:left;width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>r.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></td> <td style="text-align:left;width:auto;vertical-align:top"> <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Concentration of credit risk:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></div> </td> </tr> <tr> <td style="width:56.7pt"> </td> <td style="text-align:left;width:18pt;vertical-align:top"> </td> <td style="text-align:left;width:auto;vertical-align:top"> </td> </tr> <tr> <td style="width:56.7pt"> </td> <td style="text-align:left;width:18pt;vertical-align:top"> </td> <td style="text-align:left;width:auto;vertical-align:top"> <div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Financial </span></span></span></span></span></span></span></span></span></span></span></span></span>instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, trade receivables, marketable securities, bank deposits and restricted deposits.</span></span></span></span></span></span></span></span></div> <div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"> </div> <div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>The majority of the Company’s cash and cash equivalents and short-term bank deposits are invested with major banks in Israel. The Company believes that the financial institutions that hold the Company’s cash deposits are financially sound and, accordingly, bear minimal risk.</span></span></span></div> </td> </tr> </table> <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;border:0px;width:100%"> <tr> <td style="width:56.7pt"> </td> <td style="text-align:left;width:18pt;vertical-align:top"> </td> <td style="text-align:left;width:auto;vertical-align:top"> <div style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Trade receivables of the Company are mainly derived from customers located globally. The Company mitigates its credit risks by performing credit evaluations of its customers’ financial conditions and requires customer advance payments in certain circumstances. The Company generally does not require collateral.</span></p> <p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"> </p> </div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"> <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Company invests in marketable securities with an average credit rating of “A” and a maturity of up to three years. The Company’s investment policy is not to invest more than 5% of its investment portfolio in a single security at time of purchase.</span></p> </div> </td> </tr> </table> </div>
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	136185264	shares
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	941000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1868000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4236000	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	997000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1290000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1500000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1333000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	147000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	40208000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17167000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9719000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25770000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30489000	usd
CY2023	us-gaap	Depreciation Depreciation	7195000	usd
CY2022	us-gaap	Depreciation Depreciation	7110000	usd
CY2021	us-gaap	Depreciation Depreciation	3361000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26927000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3720000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30201000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	33921000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y11M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0455	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	3788000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	274000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	75000	usd
CY2023	invz	Operating Cash Flows From Lease Incentives Received Net Of Cash Paid For Operating Leases OperatingCashFlowsFromLeaseIncentivesReceivedNetOfCashPaidForOperatingLeases	-3072000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4453000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4456000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	21976000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	39450000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6941000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	165387098	shares
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6174000	usd
CY2023Q4	invz	Fixed Assets Creditors Current FixedAssetsCreditorsCurrent	182000	usd
CY2022Q4	invz	Fixed Assets Creditors Current FixedAssetsCreditorsCurrent	814000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	193000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	254000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8743000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7572000	usd
CY2020Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	371000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y7M2D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y7M9D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y4M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.67	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.66	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.64	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.043	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0455	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0154	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0436	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0048	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0101	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.24
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19724000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	474344	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.95
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	631970	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	396135	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.41
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	197799	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.38
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13329436	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.38
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22320000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19449000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	64736000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	51352000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M9D
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	544000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	125170000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	94973000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	19212000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	18728000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1732000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	727000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1022000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	311000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3020000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	158918000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	152965000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-125228000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-127631000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-153091000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2416000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1084000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-184000	usd
CY2023	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-122812000	usd
CY2022	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-126547000	usd
CY2021	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-153275000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	642000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	325000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	284000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	131000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	115000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	232000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	511000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	210000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0387	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0277	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.02	pure
CY2023	invz	Effective Income Tax Rate Reconciliation Effect Of Other Permanent Differences EffectiveIncomeTaxRateReconciliationEffectOfOtherPermanentDifferences	-0.0031	pure
CY2022	invz	Effective Income Tax Rate Reconciliation Effect Of Other Permanent Differences EffectiveIncomeTaxRateReconciliationEffectOfOtherPermanentDifferences	0.0005	pure
CY2021	invz	Effective Income Tax Rate Reconciliation Effect Of Other Permanent Differences EffectiveIncomeTaxRateReconciliationEffectOfOtherPermanentDifferences	0.0047	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2771	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.187	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2441	pure
CY2023	invz	Effective Income Tax Rate Reconciliation Issuance Costs EffectiveIncomeTaxRateReconciliationIssuanceCosts	0.0652	pure
CY2022	invz	Effective Income Tax Rate Reconciliation Issuance Costs EffectiveIncomeTaxRateReconciliationIssuanceCosts	0.0606	pure
CY2021	invz	Effective Income Tax Rate Reconciliation Issuance Costs EffectiveIncomeTaxRateReconciliationIssuanceCosts	0.0368	pure
CY2023	invz	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	0.0024	pure
CY2022	invz	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	-0.08	pure
CY2021	invz	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	-0.0077	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0014	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0016	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0052	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0026	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0019	pure
CY2023	us-gaap	Profit Loss ProfitLoss	-123454000	usd
CY2023	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	0	usd
CY2022	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	0	usd
CY2021	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	5044000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-123454000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-126872000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135224312	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102859891	shares
CY2021Q4	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	2178000	usd
CY2021Q4	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	2012000	usd
CY2022	us-gaap	Revenues Revenues	6026000	usd
CY2021	us-gaap	Revenues Revenues	5466000	usd
CY2023Q4	invz	Amount Of Long Lived Assets AmountOfLongLivedAssets	51256000	usd
CY2022Q4	invz	Amount Of Long Lived Assets AmountOfLongLivedAssets	57416000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001835654
CY2023	dei	Entity Registrant Name EntityRegistrantName	INNOVIZ TECHNOLOGIES LTD.
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	165387098	shares
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	1309
CY2023	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2023	dei	Auditor Name AuditorName	Kesselman & Kesselman
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	41681000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	2543000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25770000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30489000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	25486000	usd
CY2023Q4	invz	Deferred Revenues Non Current DeferredRevenuesNonCurrent	0	usd
CY2022Q4	invz	Deferred Revenues Non Current DeferredRevenuesNonCurrent	61000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	28715000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	165387098	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	165387098	shares
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-157653000	usd
CY2023	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	9790000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	325000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	284000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-123454000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-126872000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153559000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2022	invz	Exercise Of Public Warrants Value ExerciseOfPublicWarrantsValue	1000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	19449000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-126872000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	192017000	usd
CY2023	invz	Share Issue During Issuance Of Ordinary Shares Net Of Issuance Costs Value ShareIssueDuringIssuanceOfOrdinarySharesNetOfIssuanceCostsValue	61400000	usd
CY2023	invz	Adjustment To Additional Paid In Capital Reclassification Of Warrant Liabilities To Equity AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesToEquity	8000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	456000	usd
CY2023	invz	Restricted Share Units Vested Value RestrictedShareUnitsVestedValue	0	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	22862000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-123454000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	153289000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9192000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7472000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3960000	usd
CY2023	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-472000	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-890000	usd
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-1216000	usd
CY2023	invz	Issuance Cost Allocated To Warrants Liability IssuanceCostAllocatedToWarrantsLiability	0	usd
CY2022	invz	Issuance Cost Allocated To Warrants Liability IssuanceCostAllocatedToWarrantsLiability	0	usd
CY2021	invz	Issuance Cost Allocated To Warrants Liability IssuanceCostAllocatedToWarrantsLiability	1830000	usd
CY2023	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	1051000	usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	705000	usd
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	436000	usd
CY2023	invz	Fair Valuation Of Marketable Securities FairValuationOfMarketableSecurities	-409000	usd
CY2022	invz	Fair Valuation Of Marketable Securities FairValuationOfMarketableSecurities	375000	usd
CY2021	invz	Fair Valuation Of Marketable Securities FairValuationOfMarketableSecurities	104000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	22320000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-20000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2092000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	29000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1974000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	262000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-421000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82522000	usd
CY2023	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	usd
CY2022	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	usd
CY2021	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	56000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	103910000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	83461000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	30103000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	53910000	usd
CY2022	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-281597000	usd
CY2023	invz	Cash Received In Connection With Reverse Merger Net Of Issuance Costs CashReceivedInConnectionWithReverseMergerNetOfIssuanceCosts	0	usd
CY2022	invz	Cash Received In Connection With Reverse Merger Net Of Issuance Costs CashReceivedInConnectionWithReverseMergerNetOfIssuanceCosts	0	usd
CY2023	invz	Issuance Of Ordinary Share Net Of Issuance Cost IssuanceOfOrdinaryShareNetOfIssuanceCost	61400000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2638000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61856000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	609000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	337178000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	515000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1139000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	716000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29618000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31413000	usd
CY2022	invz	Non Cash Purchase Of Property And Equipment NonCashPurchaseOfPropertyAndEquipment	2335000	usd
CY2021	invz	Non Cash Purchase Of Property And Equipment NonCashPurchaseOfPropertyAndEquipment	1433000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	29000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4436000	usd
CY2023	invz	Issuance Cost Paid In Equity IssuanceCostPaidInEquity	0	usd
CY2022	invz	Issuance Cost Paid In Equity IssuanceCostPaidInEquity	0	usd
CY2021	invz	Issuance Cost Paid In Equity IssuanceCostPaidInEquity	77250000	usd
CY2023	invz	Right Of Use Asset Recognized With Corresponding Lease Liability RightOfUseAssetRecognizedWithCorrespondingLeaseLiability	868000	usd
CY2022	invz	Right Of Use Asset Recognized With Corresponding Lease Liability RightOfUseAssetRecognizedWithCorrespondingLeaseLiability	30078000	usd
CY2021	invz	Right Of Use Asset Recognized With Corresponding Lease Liability RightOfUseAssetRecognizedWithCorrespondingLeaseLiability	0	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26283000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26283000	usd
CY2023Q4	invz	Short Term Deposits ShortTermDeposits	105750000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	18148000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt" width="100%"> <tr style="page-break-inside:avoid"> <td style="width:56.7pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>b.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></td> <td style="text-align:left;width:auto;vertical-align:top"> <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>Use of estimates:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></div> </td> </tr> <tr> <td style="width:56.7pt"> </td> <td style="width:18pt;vertical-align:top"> </td> <td style="width:auto;vertical-align:top"> </td> </tr> <tr> <td style="width:56.7pt"> </td> <td style="width:18pt;vertical-align:top"> </td> <td style="text-align:left;width:auto;vertical-align:top"> <div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span>The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></div> </td> </tr> <tr> <td style="width:56.7pt"> </td> <td style="width:18pt;vertical-align:top"> </td> <td style="width:auto;vertical-align:top"> </td> </tr> <tr> <td style="width:56.7pt"> </td> <td style="width:18pt;vertical-align:top"> </td> <td style="text-align:left;width:auto;vertical-align:top"> <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Significant items subject to such estimates and assumptions include inventory reserves and useful lives of property, plant, and equipment. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from those estimates.</span></span></span></span></span></span></span></span></p> </td> </tr> </table> </div>
CY2023	invz	Impairment Of Long Lived Assets ImpairmentOfLongLivedAssets	1997000	usd
CY2022	invz	Impairment Of Long Lived Assets ImpairmentOfLongLivedAssets	362000	usd
CY2021	invz	Impairment Of Long Lived Assets ImpairmentOfLongLivedAssets	599000	usd
CY2023	invz	Revenues From Application Engineering Services RevenuesFromApplicationEngineeringServices	15225000	usd
CY2023Q4	invz	Upfront Payments Related To Application Engineering Services UpfrontPaymentsRelatedToApplicationEngineeringServices	6145000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3096000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	136000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7339000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	60000	usd
CY2023	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	361000	usd
CY2022	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	620000	usd
CY2023	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	106000	usd
CY2022	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	350000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	585000	usd
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	3723000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	3586000	usd
CY2021	us-gaap	Severance Costs1 SeveranceCosts1	2891000	usd
CY2023	invz	Percentage Of Investment Portfolio Not To Invest More In Single Security At Time Of Purchase PercentageOfInvestmentPortfolioNotToInvestMoreInSingleSecurityAtTimeOfPurchase	0.05	pure
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	640000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1053000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	803000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2242000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	425000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	6938000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	3166000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	4359000	usd
CY2023Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	3130000	usd
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	0	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	613000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3236000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	42937000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	25486000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4034000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28475000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	32509000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0459	pure
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	4455000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	13000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	175000	usd
CY2022	invz	Operating Cash Flows From Lease Incentives Received Net Of Cash Paid For Operating Leases OperatingCashFlowsFromLeaseIncentivesReceivedNetOfCashPaidForOperatingLeases	5314000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4119000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4446000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	32509000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	585000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	330000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7783000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	165387098	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	136185264	shares
CY2021Q1	invz	Stockholders Equity Reverse Stock Split Ratio StockholdersEquityReverseStockSplitRatio	1.138974	pure
CY2021Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2023Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	26352878	shares
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.5
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.5
CY2023Q3	invz	Proceeds From Issuance Of Common Stock Net Of Issuance Cost ProceedsFromIssuanceOfCommonStockNetOfIssuanceCost	61400000	usd
CY2023Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4482000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14080996	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.72
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1444000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y25D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9584000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10580281	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y11M19D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8954000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.35
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.75
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	1900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	90000	usd
CY2023Q4	invz	Deferred Tax Assets Inventory Provision DeferredTaxAssetsInventoryProvision	1608000	usd
CY2022Q4	invz	Deferred Tax Assets Inventory Provision DeferredTaxAssetsInventoryProvision	948000	usd
CY2023Q4	invz	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	5855000	usd
CY2022Q4	invz	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	6328000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2419000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	125125000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	118932000	usd
CY2023Q4	invz	Deferred Tax Liabilities Rightofuse Assets DeferredTaxLiabilitiesRightofuseAssets	-5862000	usd
CY2022Q4	invz	Deferred Tax Liabilities Rightofuse Assets DeferredTaxLiabilitiesRightofuseAssets	-6193000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-91000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5953000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6193000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	52000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	642000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	325000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	284000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2023	invz	Effective Income Tax Rate Reconciliation Capital Losses EffectiveIncomeTaxRateReconciliationCapitalLosses	0.0147	pure
CY2022	invz	Effective Income Tax Rate Reconciliation Capital Losses EffectiveIncomeTaxRateReconciliationCapitalLosses	0	pure
CY2021	invz	Effective Income Tax Rate Reconciliation Capital Losses EffectiveIncomeTaxRateReconciliationCapitalLosses	0	pure
CY2022	us-gaap	Profit Loss ProfitLoss	-126872000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-153559000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-158603000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147480521	shares
CY2023	us-gaap	Revenues Revenues	20876000	usd

Files In Submission

Name	View Source	Status
0001178913-24-000910-index-headers.html	Edgar Link	pending
0001178913-24-000910-index.html	Edgar Link	pending
0001178913-24-000910.txt	Edgar Link	pending
0001178913-24-000910-xbrl.zip	Edgar Link	pending
exhibit_12-1.htm	Edgar Link	pending
exhibit_12-2.htm	Edgar Link	pending
exhibit_13-1.htm	Edgar Link	pending
exhibit_13-2.htm	Edgar Link	pending
exhibit_15-1.htm	Edgar Link	pending
exhibit_15-2.htm	Edgar Link	pending
exhibit_4-16.htm	Edgar Link	pending
exhibit_8-1.htm	Edgar Link	pending
exhibit_97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image0.jpg	Edgar Link	pending
image00003.jpg	Edgar Link	pending
image00004.jpg	Edgar Link	pending
image00006.jpg	Edgar Link	pending
image1.jpg	Edgar Link	pending
image2.jpg	Edgar Link	pending
invz-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
invz-20231231_cal.xml	Edgar Link	unprocessable
invz-20231231_def.xml	Edgar Link	unprocessable
invz-20231231_pre.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zk2431063.htm	Edgar Link	pending
invz-20231231_lab.xml	Edgar Link	unprocessable
zk2431063_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INVZ
Innoviz Technologies Ltd. Stock $invz

2023 Q4 Form 20-F Financial Statement

#000117891324000910 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INVZ Innoviz Technologies Ltd. Stock $invz

2023 Q4 Form 20-F Financial Statement

#000117891324000910 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INVZ
Innoviz Technologies Ltd. Stock $invz